Human leukocyte antigen (HLA) class II peptide flanking residues tune the immunogenicity of a human tumor-derived epitope

Documenti analoghi

• The nature of the human T cell response to the cancer antigen 5T4 is determined by the balance of regulatory and inflammatory T cells of the same antigen-specificity: implications for vaccine design
  di: Besneux, Matthieu, et al.
  Pubblicazione: (2018)
• Molecular characterization of HLA class II binding to the LAG‐3 T cell co‐inhibitory receptor
  di: MacLachlan, Bruce J., et al.
  Pubblicazione: (2020)
• Enhanced Detection of Antigen-Specific CD4(+) T Cells Using Altered Peptide Flanking Residue Peptide–MHC Class II Multimers
  di: Holland, Christopher J., et al.
  Pubblicazione: (2015)
• Regulatory T cells and tumour immunity – observations in mice and men
  di: Gallimore, Awen, et al.
  Pubblicazione: (2008)
• Hunting for clues: Regulatory T cells and colorectal cancer
  di: Gallimore, Awen, et al.
  Pubblicazione: (2012)